A Monoclonal Antibody Specific for Japanese Encephalitis Virus with High Neutralizing Capability for Inclusion as a Positive Control in Diagnostic Neutralization Tests.


Journal

The American journal of tropical medicine and hygiene
ISSN: 1476-1645
Titre abrégé: Am J Trop Med Hyg
Pays: United States
ID NLM: 0370507

Informations de publication

Date de publication:
07 2019
Historique:
pubmed: 23 5 2019
medline: 22 1 2020
entrez: 23 5 2019
Statut: ppublish

Résumé

Japanese encephalitis virus (JEV) is the most common cause of viral encephalitis in Asia, and it is increasingly a global public health concern because of its recent geographic expansion. Although commercial vaccines are available and used in some endemic countries, JEV continues to cause illness, with more than 60,000 cases reported annually. To develop a reproducible positive control antibody useable in diagnosis of JEV infections, murine hybridomas were developed from mice inoculated with a combination of IXIARO JEV vaccine and JEV domain III of the envelope protein (E-DIII). Monoclonal antibodies (MAbs) were characterized for their ability to neutralize virus in vitro. Monoclonal antibody 17BD3-2 was found to be JEV specific and highly neutralizing, with a plaque reduction neutralization test (PRNT)

Identifiants

pubmed: 31115302
doi: 10.4269/ajtmh.19-0073
pmc: PMC6609188
doi:

Substances chimiques

Antibodies, Monoclonal 0
Antibodies, Neutralizing 0
Antibodies, Viral 0
Viral Envelope Proteins 0
Viral Vaccines 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

233-236

Subventions

Organisme : NIAID NIH HHS
ID : U54 AI065357
Pays : United States

Références

Virology. 2005 May 25;336(1):70-82
pubmed: 15866072
Nature. 1975 Aug 7;256(5517):495-7
pubmed: 1172191
J Gen Virol. 2006 Feb;87(Pt 2):339-46
pubmed: 16432020
Nature. 2005 Sep 29;437(7059):764-9
pubmed: 16193056
Wkly Epidemiol Rec. 2015 Feb 27;90(9):69-87
pubmed: 25726573
J Virol. 1993 Mar;67(3):1269-77
pubmed: 7679745
Annu Rev Entomol. 2009;54:17-35
pubmed: 19067628
Zoonoses Public Health. 2009 Aug;56(6-7):338-56
pubmed: 19486319
Am J Trop Med Hyg. 1998 May;58(5):655-62
pubmed: 9598457
mBio. 2018 Feb 27;9(1):
pubmed: 29487230
J Virol. 2011 Mar;85(5):1994-2003
pubmed: 21147919
Vaccine. 2014 Jan 3;32(2):258-64
pubmed: 24252694
Virology. 2013 Jul 5;441(2):114-25
pubmed: 23571092
J Virol. 2010 Oct;84(20):10630-43
pubmed: 20702644
J Gen Virol. 1989 Aug;70 ( Pt 8):2037-49
pubmed: 2549181
J Virol. 2005 Jun;79(12):7300-10
pubmed: 15919884
Nat Med. 2005 May;11(5):522-30
pubmed: 15852016
Virology. 1991 Mar;181(1):70-7
pubmed: 1704661

Auteurs

Amanda E Calvert (AE)

Arboviral Diseases Branch, Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention, Fort Collins, Colorado.

Susan L Bennett (SL)

Arthropod-Borne and Infectious Diseases Laboratory, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado.

Kandice L Dixon (KL)

Arboviral Diseases Branch, Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention, Fort Collins, Colorado.

Carol D Blair (CD)

Arthropod-Borne and Infectious Diseases Laboratory, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado.

John T Roehrig (JT)

Arboviral Diseases Branch, Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention, Fort Collins, Colorado.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH